182 related articles for article (PubMed ID: 19955801)
1. Altered fractionation schemes in radiotherapy.
Stuschke M; Pöttgen C
Front Radiat Ther Oncol; 2010; 42():150-156. PubMed ID: 19955801
[TBL] [Abstract][Full Text] [Related]
2. A new index comparable to BED for evaluating the biological efficacy of hypofractionated radiotherapy schemes on early stage non-small cell lung cancer: analysis of data from the literature.
Kong C; Guo WJ; Zha WW; Zhu XZ; Huang SF; Zhang YW; Xu JH; He X
Lung Cancer; 2014 Apr; 84(1):7-12. PubMed ID: 24548340
[TBL] [Abstract][Full Text] [Related]
3. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
[TBL] [Abstract][Full Text] [Related]
4. Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma.
Liu F; Farris MK; Ververs JD; Hughes RT; Munley MT
Radiother Oncol; 2024 Jun; 195():110257. PubMed ID: 38548113
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy With Curative Intent in Patients With Early-stage, Medically Inoperable, Non-Small-cell Lung Cancer: A Systematic Review.
Falkson CB; Vella ET; Yu E; El-Mallah M; Mackenzie R; Ellis PM; Ung YC
Clin Lung Cancer; 2017 Mar; 18(2):105-121.e5. PubMed ID: 27908621
[TBL] [Abstract][Full Text] [Related]
6. Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapy.
Klement RJ; Sonke JJ; Allgäuer M; Andratschke N; Appold S; Belderbos J; Belka C; Dieckmann K; Eich HT; Flentje M; Grills I; Eble M; Hope A; Grosu AL; Semrau S; Sweeney RA; Hörner-Rieber J; Werner-Wasik M; Engenhart-Cabillic R; Ye H; Guckenberger M
Radiother Oncol; 2020 Jan; 142():210-216. PubMed ID: 31431371
[TBL] [Abstract][Full Text] [Related]
7. [Outcome of three-dimensional conformal radiotherapy for early stage non-small cell lung cancer patients who met or not inclusion criteria for stereotactic-body radiation therapy].
Kołodziejczyk M; Kępka L; Tyc-Szczepaniak D; Wierzchowski M
Pneumonol Alergol Pol; 2011; 79(5):326-36. PubMed ID: 21861256
[TBL] [Abstract][Full Text] [Related]
8. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ
J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394
[TBL] [Abstract][Full Text] [Related]
9. Impact of SBRT fractionation in hypoxia dose painting - Accounting for heterogeneous and dynamic tumor oxygenation.
Kjellsson Lindblom E; Ureba A; Dasu A; Wersäll P; Even AJG; van Elmpt W; Lambin P; Toma-Dasu I
Med Phys; 2019 May; 46(5):2512-2521. PubMed ID: 30924937
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study.
Onishi H; Shirato H; Nagata Y; Hiraoka M; Fujino M; Gomi K; Niibe Y; Karasawa K; Hayakawa K; Takai Y; Kimura T; Takeda A; Ouchi A; Hareyama M; Kokubo M; Hara R; Itami J; Yamada K; Araki T
J Thorac Oncol; 2007 Jul; 2(7 Suppl 3):S94-100. PubMed ID: 17603311
[TBL] [Abstract][Full Text] [Related]
11. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E
Christ SM; Alongi F; Ricardi U; Scorsetti M; Livi L; Balermpas P; Lievens Y; Braam P; Jereczek-Fossa BA; Stellamans K; Ratosa I; Widder J; Peulen H; Dirix P; Bral S; Ramella S; Hemmatazad H; Khanfir K; Geets X; Jeene P; Zilli T; Fournier B; Ivaldi GB; Clementel E; Fortpied C; Oppong FB; Ost P; Guckenberger M
Radiother Oncol; 2024 Jun; 195():110235. PubMed ID: 38508239
[TBL] [Abstract][Full Text] [Related]
12. Optimal fractionation in radiotherapy for non-small cell lung cancer--a modelling approach.
Lindblom E; Dasu A; Toma-Dasu I
Acta Oncol; 2015; 54(9):1592-8. PubMed ID: 26217986
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review.
Nguyen LN; Komaki R; Allen P; Schea RA; Milas L
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1053-6. PubMed ID: 10421538
[TBL] [Abstract][Full Text] [Related]
14. High-dose hyperfractionated accelerated radiotherapy in non-small cell lung cancer.
De Ruysscher D; Reymen B; Van Baardwijk A
Minerva Chir; 2011 Aug; 66(4):341-5. PubMed ID: 21873969
[TBL] [Abstract][Full Text] [Related]
15. Optimal Radiation Therapy Fractionation Regimens for Early-Stage Non-Small Cell Lung Cancer.
Liu F; Ververs JD; Farris MK; Blackstock AW; Munley MT
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):829-838. PubMed ID: 37734445
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
[TBL] [Abstract][Full Text] [Related]
18. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
Jeremić B; Milicić B
Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
[TBL] [Abstract][Full Text] [Related]
19. SBRT for centrally localized NSCLC - What is too central?
Roesch J; Panje C; Sterzing F; Mantel F; Nestle U; Andratschke N; Guckenberger M
Radiat Oncol; 2016 Dec; 11(1):157. PubMed ID: 27912764
[TBL] [Abstract][Full Text] [Related]
20. A treatment planning study evaluating a 'simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer.
Dirkx ML; van Sörnsen De Koste JR; Senan S
Lung Cancer; 2004 Jul; 45(1):57-65. PubMed ID: 15196735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]